Disease Domain | Count |
---|---|
Hemic and Lymphatic Diseases | 2 |
Neoplasms | 2 |
Infectious Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Chemical drugs | 1 |
Target |
Mechanism HCK inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PfCLK3 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism c-Met inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date30 Sep 2024 |
Sponsor / Collaborator |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
iHCK-37 ( HCK ) | Myeloid Leukemia More | Preclinical |
TCMDC-135051 ( PfCLK3 ) | Malaria, Falciparum More | Preclinical |
B-2000 ( c-Met ) | Acute Myeloid Leukemia More | Preclinical |
DHFR inhibitors(University of Campinas) ( DHFR ) | Mycobacterium Abscessus Infection More | Discovery |
WP-1122 ( SARS-CoV-2 S protein ) | COVID-19 More | Pending |